Evaluating the Efficacy of Primary Treatment for Graves’ Disease Complicated by Thyrotoxic Periodic Paralysis
Table 3
A summary of the clinical course of the 16 patients with thyrotoxic periodic paralysis secondary to Graves’ disease (TPP/GD).
Patient number
Sex/age (years)
Primary treatment modality
Interval to first thyrotoxic relapse (months)
Treatment for first thyrotoxic relapse
Interval to second thyrotoxic relapse (months)
Treatment for second thyrotoxic relapse
Follow-up period (months)
Thyroid function status on latest follow-up
1*
M/31
ATD
22
ATD
25
Surgery
68.0
T4
2
M/33
ATD
76#
ATD
20
ATD
124.8
Hyperthyroid
3*
M/17
ATD
35#
ATD
ATD
86.3
Hyperthyroid
4*
M/25
ATD
40
ATD
52
Surgery
113.7
T4
5*
M/32
ATD
28
RAI 250 MBq
12
RAI 250 MBq
154.3
T4
6
M/23
ATD
247#
RAI 350 MBq
RAI 350 MBq
293.2
T4
7
M/27
ATD
102#
RAI 250 MBq
RAI 300 MBq
146.1
T4
8*
M/24
ATD
29
Surgery
—
—
66.0
T4
9*
M/33
RAI 300 MBq
29#
ATD
—
—
87.3
Euthyroid
10*
M/23
RAI 350 MBq
12
RAI 300 MBq
—
—
49.7
T4
11*
M/39
RAI 300 MBq
—
—
—
—
22.4
Euthyroid
12*
M/42
RAI 350 MBq
—
—
—
—
96.5
T4
13*
M/45
Surgery
—
—
—
—
11.2
T4
14*
F/26
Surgery
—
—
—
—
152.2
T4
15*
M/32
Surgery
—
—
—
—
19.3
T4
16
M/39
Surgery
—
—
—
—
125.6
T4
GD/TPP: thyrotoxic periodic paralysis secondary to Graves’ disease; ATD: antithyroid drugs; RAI: 131I or radioactive iodine; T4: requiring daily thyroxine replacement. Note: the primary treatment of patient 7 was switched to PTU due to allergy to CMZ. Where TPP was the first presenting symptom of thyrotoxicosis. Patient who had an attack of TPP during the first thyrotoxic relapse. Patient who had an attack of TPP during the second thyrotoxic relapse.
